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The efficacy of GnRH agonists (GnRHa) as a method for protecting fertility has been controversially 
discussed for years. This is clearly demonstrated by the fact that there are now more meta-analyses 
on this subject than individual studies. However, the discussion is often not conducted objectively 
but seems to be shaped by fundamental ideologies, leading to a scientific dispute between GnRHa 
advocates and GnRHa opponents. A new study now adds even more fuel to the fire of the discussion 
because it investigated the long-term protective effect of GnRHa on the ovaries for the first time and 
was not able to demonstrate a long-term effect (1).
Based on this, it is not time for us to evaluate the overall effectiveness of GnRHa, or even allow 
ourselves to be led by ideologies, but to consider the existing studies and their target criteria in an 
objective and differentiated manner. Different criteria were defined in the study which, due to their 
diversity, has the disadvantage that the studies cannot be evaluated in the same way and is certainly 
one of the reasons for the controversial data situation. On the other hand, this has the great advantage 
that due to the different target criteria, different aspects of GnRHa effects have been analyzed, and 
the effectiveness of GnRHa can therefore be assessed from different perspectives.
In the studies, the following criteria were defined to assess the effect of GnRHa:
 1. Short-term risk of premature ovarian insufficiency (POI) rate
 2. Long-term ovarian reserve after chemotherapy
 3. Pregnancy rate after chemotherapy.
Ad 1: most studies addressed the POI rate as the primary endpoint. POI was defined as amenor-
rhea or oligomenorrhea and/or as increased FSH concentrations. A meta-analysis (2) and the very 
recently presented OPTION randomized controlled trial performed in the UK (3) provide strong 
evidence that GnRHa do have a short-term effect (1–2  years after chemotherapy) in reducing 
the risk of developing POI. Lambertini et  al. (2) included 12 RCTs composed of 1,231 breast 
cancer patients in a meta-analysis. Odds ratios (ORs) and 95% confidence intervals (CIs) for POI 
(POI defined by study definition or as amenorrhea 1 year after chemotherapy completion) were 
calculated for each trial. The use of GnRHa was associated with a significantly reduced risk of POI 
(OR 0.36, 95% CI 0.23–0.57), yet with significant heterogeneity. In eight studies, defining POI 
as amenorrhea rates 1 year after chemotherapy completion, the addition of GnRHa reduced the 
risk of POI (OR 0.55, 95% CI 0.41–0.73) with less heterogeneity. A recently published RCT (3) 
confirmed this result. A total of 140 women with breast cancer were randomized to receive either 
GnRHa or no GnRHa. In the GnRHa group, 77.9% of women resumed menstruation, compared 
to only 61.7% in the group without GnRHa (p = 0.015).
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Ad 2: the long-term effects of GnRHa have so far only been 
analyzed by a recently published study by Demeestere et al. (1). 
This single study provides evidence that GnRHa do not have a 
long-term protective effect (5–7 years after chemotherapy) on 
the ovarian reserve. Demeestere et al. (1) randomly assigned a 
total of 129 patients with lymphoma to receive either GnRHa 
group or norethisterone alone. The primary end point was POI, 
defined as at least one follicle-stimulating hormone value of 
>40 IU/L. A multivariate logistic regression analysis showed a 
significantly increased risk of POI in patients according to age, 
but with the coadministration of GnRHa during chemotherapy 
(OR  =  0.70, 95% CI 0.15–3.24). However, a more detailed 
analysis of the data revealed that even though FSH concentra-
tions were almost equal a few years after the end of the chemo-
therapy, indicating no long-term effect, FSH concentrations 
were significantly lower in the GnRHa group just after the end 
of chemotherapy, indicating a possible short-term protective 
effect of GnRHa, as described above. However, it should be 
noted that this is the first and only study of the long-term pro-
tective effect of GnRHa on the ovaries and further confirmatory 
studies have to be awaited.
Ad 3: the pregnancy rate after chemotherapy has been addressed 
by a few studies. These few studies provide some evidence that 
fertility, defined as the pregnancy rate following chemotherapy, 
is not reduced. Yang et al. (4) included five RCTs composed of 
528 breast cancer patients in a meta-analysis. Significantly fewer 
women treated with GnRHa experienced POI (RR = 0.40, 95% 
CI 0.21–0.75). By contrast, both treatment groups experienced 
similar rates of spontaneous pregnancy (RR  =  0.96, 95% CI 
0.20–4.56).
All three outcome criteria have the aim of investigating the 
effectiveness of GnRHa and therefore determining whether 
they can be recommended as a fertility preservation measure. 
However, they refer to different fertility relevant factors, which 
do not allow a standard conclusion to be made in a clinical 
context.
The different clinical relevance of studies with various end-
points is clearly demonstrated by a meta-analysis (4), which 
showed that GnRHa reduce the chemotherapy-induced risk of 
POI in breast cancer patients but do not increase the birth rate. 
What appears here to be a contradiction at first sight is, however, 
probably not contradictory on closer examination. The small 
proportion of women who suffer from POI and are therefore only 
likely to have a low probability of having a child can be obscured 
by the large number of women who have all been made aware of 
a possible chemotherapy-induced reduction in their fertility and 
therefore quickly try to realize their desire to conceive a child after 
completion of their oncological treatment.
Comparing the endpoints “POI risk reduction” (2, 3) and “long-
term effect on the ovarian reserve” (1), these factors also have 
a different meaning in a clinical context. For example, whether 
the POI risk is reduced in the short term is very important for a 
37-year-old woman, but whether GnRHa has a long-term effect 
plays less of an important role, as she cannot become pregnant 
at 43  years for natural reasons. On the other hand, Hodgkin’s 
lymphoma patients develop the disease at a younger age and the 
long-term effects are therefore more likely to play a role in young 
women.
Of course, the differences between a short-term effect and a 
long-term effect of GnRHa raise the question of whether these 
differences can be explained physiologically. The ovarian reserve 
does not decrease linearly over the course of life; the decline slows 
with increasing age (5) and thus probably also with an increas-
ingly smaller ovarian reserve. Because of this, it is quite possible 
that the ovarian reserve of women with GnRHa treatment is even 
higher in the short term after chemotherapy than in women who 
did not receive GnRH therapy. If the ovarian reserve is higher, 
loss of follicles would occur faster over subsequent years than in 
those with a lower ovarian reserve, so the ovarian reserves align 
themselves in the long term as the study by Demeestere et  al. 
would suggest.
In summary, this means that differing study results are not 
totally contradictory. They only examine different effects of 
GnRHa and therefore evaluate their efficacy from different 
perspectives. The different effects mean that when an indication 
is made for using GnRHa, these differing effects should also be 
considered. For example, a short-term fertility preservation effect 
is relevant in women aged 35–40 years, whereas the long-term 
effects are more important in young women.
However, it should be first noted that most studies, with the 
exception of the study on the long-term effect of GnRHa, were 
carried out in women with breast cancer and second that data 
on some of the discussed effects of GnRHa are still lacking. 
As a result of this, a generalization of the study results and the 
interpretation presented in this article cannot be applied to other 
diseases with certainty.
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